希慎興業(00014.HK)附屬博威獲提供129.51億港元銀行融資
格隆匯1月25日丨希慎興業(00014.HK)發佈公吿,2022年1月25日,作為借貸人的博威(公司持有60%權益的附屬公司)與作為聯合授權牽頭安排行的授權牽頭安排行(其中包括恆生及匯豐)及貸款人(其中包括恆生及匯豐)訂立融資協議。
根據融資協議,貸款人根據融資協議將向博威提供的本金總額為129.51億港元的銀行融資(其中恆生及匯豐各自依次提供最高達18.51億港元及26億港元的融資)。貸款人包括中國銀行(香港)有限公司、中國建設銀行香港分行、星展銀行(香港)有限公司、匯豐、恆生及中國工商銀行(亞洲)有限公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.